Cureus · 2026
Demographics, Tumor Biology and Treatment Outcomes of Male Breast Cancer Patients From a Tertiary Cancer Center in North India: A Real-World Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gupta Deepak, Bapna Ajay, Gupta Anil K, Patni Sanjeev, Ledwani Naresh, Chandorkar Salila
Аннотация
BACKGROUND: Male breast cancer (MBC) is a rare malignancy, and treatment recommendations are largely extrapolated from female breast cancer data. Real-world evidence from India remains limited.
OBJECTIVE: The objective of this study is to evaluate the demographic, clinicopathological, treatment, and survival characteristics of MBC patients treated at a tertiary cancer center in India.
METHODS: This retrospective real-world study included MBC patients treated between January 2012 and January 2024. Demographic, clinicopathological, treatment, and outcome data were analyzed using descriptive statistics and Kaplan-Meier survival estimates.
RESULTS: A total of 107 patients were included. The median age at diagnosis was 62 years (range: 26-82). Left-sided disease was slightly more common (51.4%), and invasive ductal carcinoma was the predominant histology (88.8%). Eighteen patients (16.8%) presented with advanced/metastatic disease. Hormone receptor positivity was high, with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 positivity rates of 88.5%, 89.1%, and 7.7%, respectively. Modified radical mastectomy was the most common surgical procedure (75.6%). At a median follow-up of 27.9 months, the median overall survival was 111.7 months.
CONCLUSION: MBC in this study was characterized by a substantial proportion of patients presenting with advanced disease and high hormone receptor positivity. Greater awareness and earlier diagnosis may improve outcomes in this rare malignancy.
OBJECTIVE: The objective of this study is to evaluate the demographic, clinicopathological, treatment, and survival characteristics of MBC patients treated at a tertiary cancer center in India.
METHODS: This retrospective real-world study included MBC patients treated between January 2012 and January 2024. Demographic, clinicopathological, treatment, and outcome data were analyzed using descriptive statistics and Kaplan-Meier survival estimates.
RESULTS: A total of 107 patients were included. The median age at diagnosis was 62 years (range: 26-82). Left-sided disease was slightly more common (51.4%), and invasive ductal carcinoma was the predominant histology (88.8%). Eighteen patients (16.8%) presented with advanced/metastatic disease. Hormone receptor positivity was high, with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 positivity rates of 88.5%, 89.1%, and 7.7%, respectively. Modified radical mastectomy was the most common surgical procedure (75.6%). At a median follow-up of 27.9 months, the median overall survival was 111.7 months.
CONCLUSION: MBC in this study was characterized by a substantial proportion of patients presenting with advanced disease and high hormone receptor positivity. Greater awareness and earlier diagnosis may improve outcomes in this rare malignancy.